MedTrace Logo

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-21

No results posted yet for this study

Summary

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Conditions

Interventions

DRUG

Tacabrutideg

Administered orally

DRUG

Sonrotoclax

Administered orally

DRUG

Zanubrutinib

Administered orally

DRUG

Mosunetuzumab

Administered subcutaneously

DRUG

Glofitamab

Administered intravenously

DRUG

Obinutuzumab

Administered intravenously

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-27
Primary Completion
2028-12-02
Completion
2029-12-02
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • China
  • Germany
  • Italy
  • New Zealand
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06634589 on ClinicalTrials.gov